Sanofi and Orano Med Partner to Drive Development of Advanced Radioligand Cancer Therapies

Sanofi and Orano Med Partner to Drive Development of Advanced Radioligand Cancer Therapies

(IN BRIEF) Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare cancers. By combining their expertise, they aim to advance treatments using lead-212 (212Pb) alpha-emitting isotopes, which target and destroy cancer cells while minimizing damage to healthy tissue. Sanofi will invest €300 million into a new entity operating under the Orano Med brand, which will focus on designing and developing these innovative therapies. The collaboration reflects both companies’ commitment to advancing oncology innovation, particularly for difficult-to-treat cancers.

(PRESS RELEASE) PARIS, 18-Oct-2024 — /EuropaWire/ — Sanofi and Orano Med, a subsidiary of Orano Group, have joined forces to accelerate the development of cutting-edge radioligand therapies (RLTs) targeting rare cancers. Through this collaboration, both companies will invest in a new entity operating under the Orano Med brand, focused on designing and advancing next-generation RLTs based on lead-212 (212Pb) alpha-emitting isotopes. This partnership follows Sanofi’s licensing agreement with Orano Med and RadioMedix to advance radioligand treatments like AlphaMedix™.

Radioligand therapy combines biological targeting vectors with powerful alpha-emitting radioisotopes to selectively destroy cancer cells while minimizing harm to healthy tissue. The approach offers potential for treating rare cancers by improving patient outcomes and extending lives.

Sanofi’s CEO, Paul Hudson, highlighted the significance of this partnership, emphasizing the synergy between Sanofi’s biopharmaceutical expertise and Orano’s leadership in nuclear technology. Nicolas Maes, CEO of Orano, also underlined how this collaboration demonstrates Orano’s ability to apply its nuclear expertise to healthcare innovations.

Sanofi’s €300 million equity investment will further strengthen Orano Med’s global industrial platform and allow for rapid development of its lead-212 based therapies. Both companies are part of the Paris Saclay Cancer Cluster and aim to contribute to France’s 2030 plan to foster oncology innovation. The agreement is subject to regulatory approvals.

Financial Overview: Sanofi will make a €300 million equity investment, securing a 16% stake in the new entity valued at €1.9 billion.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

About Orano Med
Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company that develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). The company is developing several treatments using 212Pb combined with various targeting agents. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US and is currently investing to further expand its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe.

As a recognized international operator in the field of nuclear materials, Orano Group delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group’s 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow.

Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group apart from AlphaMedix.

Media Contacts:

Orano Med:
Sophie Letournel | +33 6 38 44 34 11| sophie.letournel@orano.group

Orano Group:
Press Office | +33 (0)1 34 96 12 15| press@orano.group

Orano Investor relations:
Marc Quesnoy | investors@orano.group

Sanofi Media Relations:
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com

Sanofi Investor Relations:
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com

SOURCE: Sanofi